Encouraging appropriate use of proton pump inhibitors: existing initiatives and proposals for the future

被引:6
|
作者
Mari, Amir [1 ,2 ]
Marabotto, Elisa [3 ]
Ribolsi, Mentore [4 ]
Zingone, Fabiana [5 ,6 ]
Barberio, Brigida [5 ,6 ]
Savarino, Vincenzo [1 ]
Savarino, Edoardo Vincenzo [5 ,6 ,7 ]
机构
[1] Nazareth EMMS Hosp, Gastroenterol Unit, Nazareth, Israel
[2] Bar Ilan Univ, Azrieli Fac Med, Nazareth, Israel
[3] Univ Genoa, Dept Internal Med, Gastroenterol Unit, Genoa, Italy
[4] Campus Bio Med Univ Rome, Dept Digest Dis, Rome, Italy
[5] Azienda Osped Univ Padova, Gastroenterol Unit, Padua, Italy
[6] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy
[7] Univ Padua, Dept Surg Oncol & Gastroenterol, Via Giustiniani 2, I-35128 Padua, Italy
关键词
Proton pump inhibitors; GERD; acid-suppressive therapy; misuse; PPI; GASTROESOPHAGEAL-REFLUX DISEASE; HELICOBACTER-PYLORI INFECTION; CRITICALLY III PATIENTS; 2 RECEPTOR ANTAGONISTS; GASTRIC-ACIDITY; PH-IMPEDANCE; STEP-DOWN; EOSINOPHILIC ESOPHAGITIS; FUNCTIONAL HEARTBURN; INAPPROPRIATE USE;
D O I
10.1080/17512433.2023.2252327
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Proton pump inhibitors (PPIs) have revolutionized the management of acid-related disorders, representing today the mainstay treatment of these conditions. However, despite their large range of indications and usefulness, the remarkable expansion of their use in the last two decades cannot be explained by the increasing prevalence of acid-related diseases only. An inappropriate prescription for clinical conditions in which the pathogenetic role of acid has not been documented has been described, with the natural consequence of increasing the costs and the potential risk of iatrogenic harm due to adverse events and complications recently emerged. Areas covered: In this review, we summarize current indications of PPIs administration, potential adverse events associated with their chronic utilization, and misuse of PPIs. Moreover, we describe existing and possible initiatives for improving the use of PPIs, and some proposals for the future. Expert opinion: PPI deprescribing is the preferred and most effective approach to reduce the use of PPIs, rather than adopting sharp discontinuation, probably due to fewer withdrawal symptoms. Nonetheless, large knowledge gaps still exist in clinical practice regarding the optimal approach of PPI deprescribing in various clinical scenarios. Further prospective well-designed international studies are eagerly warranted to improve our perspectives on controlling global PPI inappropriate use.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Reduce unnecessary use of proton pump inhibitors
    Farrell, Barbara
    Lass, Elliot
    Moayyedi, Paul
    Ward, Deanna
    Thompson, Wade
    BMJ-BRITISH MEDICAL JOURNAL, 2022, 379
  • [42] Marked increase in proton pump inhibitors use in Australia
    Hollingworth, Samantha
    Duncan, Emma L.
    Martin, Jennifer H.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 (10) : 1019 - 1024
  • [43] Use of proton pump inhibitors and risk of pancreatic cancer
    Hicks, Blanaid
    Friis, Soren
    Pottegard, Anton
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 201 - 201
  • [44] Potential Costs of Inappropriate Use of Proton Pump Inhibitors
    Ladd, Antonio Mendoza
    Panagopoulos, Georgia
    Cohen, Joshua
    Mar, Nataliya
    Graham, Robert
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2014, 347 (06): : 446 - 451
  • [45] Use of proton pump inhibitors and risk of pancreatic cancer
    Hicks, Blanaid
    Friis, Soren
    Pottegard, Anton
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 (08) : 926 - 930
  • [46] Use of proton pump inhibitors during pregnancy and breastfeeding
    Nava-Ocampo, Alejandro A.
    Velazquez-Armenta, Elvia Y.
    Han, Jung-Yeol
    Koren, Gideon
    CANADIAN FAMILY PHYSICIAN, 2006, 52 : 853 - 854
  • [47] Safety of Concomitant Use of Proton Pump Inhibitors and Clopidogrel
    Khawaja, Owais
    Al-Mallah, Mouaz H.
    AMERICAN JOURNAL OF MEDICINE, 2010, 123 (04): : E11 - E11
  • [48] Concomitant use of capecitabine and proton pump inhibitors - Is it safe?
    Cheng, Vian
    de Lemos, Mario
    Hunter, Nicole
    Badry, Nadine
    de Lemos, Jane
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (07) : 1705 - 1711
  • [49] Use of proton pump inhibitors and adverse clinical outcomes
    Wu, Dan-Na
    Li, Guo-Fu
    Yu, Guo
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (05) : 2452 - 2453
  • [50] A Rationale for the Use of Proton Pump Inhibitors as Antineoplastic Agents
    De Milito, Angelo
    Marino, Maria Lucia
    Fais, Stefano
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (10) : 1395 - 1406